Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, t ...

Since the completion of the NC-11 bypass in November of 2019, Grifton has entered a “growth” phase, according to town manager Dylan Haman. The 4-lane bypass opened the doors for the town to access the ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. The biopharmaceutical company posted a loss of $11.4 million, or 11 cents ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

The SMA gene therapy candidate OAV101 IT, a version of Zolgensma, can be safely given to previously treated patients, per new trial data.

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Daiwa Securities Group Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 44.0% during the ...

Animal models had suggested that donepezil, used to stabilize dementia symptoms, may alleviate psychiatric symptoms and ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...